Author:
Zayed Aref L.,Hamadneh Ghuroob N.,Hroot Jomana Al,Mayyas Abdulraouf,Jaber Sana'a A.,Qinna Nidal A.
Funder
Deanship of Scientific Research, University of Jordan
Jordan University of Science and Technology
Subject
Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry
Reference32 articles.
1. Epidemiology of renal cell carcinoma in Germany;Fiebig;Onkologe,2019
2. FDA approval summary: tivozanib for relapsed or refractory renal cell carcinoma;Chang;Clin. Cancer Res.,2022
3. Tivozanib for the treatment of renal cell carcinoma;Santoni;Expert Opin. Pharm. [Internet],2018
4. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211810Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review;FDA,2016
5. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor;Cotreau;Clin. Pharm. Drug Dev.,2015
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献